Please ensure Javascript is enabled for purposes of website accessibility

Wall Street Is Out of Patience With This Biotech

By Dave Williamson – Mar 14, 2013 at 8:38PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cancer drug hopeful Geron gets hit with a downgrade.

Geron (GERN -2.06%) had a rough go of it over the last two years, as shares have lost over 70% of their value. The company controversially sold off its stem-cell business to focus on hot cancer drug candidate imetelstat. If imetelstat were a success, management would look brilliant for backing the right horse while avoiding the stem cell R&D black hole. Unfortunately, that proved to be a big if. Imetelstat's Phase 2 trial for breast cancer was cancelled, and Geron decided not to advance it to Phase 3 in NSCLC.

As Geron presses ahead with imetelstat, it is losing support from Wall Street. A Stifel Nicolaus analyst ripped the company's plans apart, calling them "flawed and sluggish," while dropping its rating all the way to sell.

Watch and find out what Motley Fool health-care analyst David Williamson thinks about Geron's downgrade, and what it means for investors. 

David Williamson has no position in any stocks mentioned. Follow David on Twitter @MotleyDavid

The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.